MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b

Nancy D. Richert; Mary Christina Zierak; Craig N. Bash; Bobbi K. Lewis; Henry F. McFarland; Joseph A. Frank

MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b

Nancy D. Richert, Mary Christina Zierak, Craig N. Bash, Bobbi K. Lewis, Henry F. McFarland, Joseph A. Frank

Research output: Contribution to journal › Article › peer-review

Abstract

Monthly MRI activity and clinical disability were evaluated in two relapsing-remitting multiple sclerosis (RRMS) patients for 4 years during a crossover treatment trial with IFNβ-1b, and for a mean of 21 months after terminating treatment with IFNβ-1b. Post-treatment MRI activity was compared to baseline activity in these patients. Although contrast enhancing lesions (CEL) and the bulk white matter lesion load (BWMLL) on T2-weighted images eventually returned to baseline values, there was a refractory period of 6 - 10 months after terminating treatment, before baseline MRI activity was restored. Although the mechanism for a sustained effect of IFNβ-1b is unclear at this time, these results have important implications for enrollment of such patients into new treatment protocols that rely on contrast enhancing lesion frequency as an outcome measure.

Original language	English (US)
Pages (from-to)	86-90
Number of pages	5
Journal	Multiple Sclerosis
Volume	6
Issue number	2
State	Published - Apr 2000
Externally published	Yes

Keywords

Interferon beta-1b
Magnetic resonance imaging
Multiple sclerosis

ASJC Scopus subject areas

Clinical Neurology

Cite this

@article{18f5c673887b43f7a116c8a42a08abb6,

title = "MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b",

abstract = "Monthly MRI activity and clinical disability were evaluated in two relapsing-remitting multiple sclerosis (RRMS) patients for 4 years during a crossover treatment trial with IFNβ-1b, and for a mean of 21 months after terminating treatment with IFNβ-1b. Post-treatment MRI activity was compared to baseline activity in these patients. Although contrast enhancing lesions (CEL) and the bulk white matter lesion load (BWMLL) on T2-weighted images eventually returned to baseline values, there was a refractory period of 6 - 10 months after terminating treatment, before baseline MRI activity was restored. Although the mechanism for a sustained effect of IFNβ-1b is unclear at this time, these results have important implications for enrollment of such patients into new treatment protocols that rely on contrast enhancing lesion frequency as an outcome measure.",

keywords = "Interferon beta-1b, Magnetic resonance imaging, Multiple sclerosis",

author = "Richert, {Nancy D.} and Zierak, {Mary Christina} and Bash, {Craig N.} and Lewis, {Bobbi K.} and McFarland, {Henry F.} and Frank, {Joseph A.}",

year = "2000",

month = apr,

language = "English (US)",

volume = "6",

pages = "86--90",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "2",

}

TY - JOUR

T1 - MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b

AU - Richert, Nancy D.

AU - Zierak, Mary Christina

AU - Bash, Craig N.

AU - Lewis, Bobbi K.

AU - McFarland, Henry F.

AU - Frank, Joseph A.

PY - 2000/4

Y1 - 2000/4

N2 - Monthly MRI activity and clinical disability were evaluated in two relapsing-remitting multiple sclerosis (RRMS) patients for 4 years during a crossover treatment trial with IFNβ-1b, and for a mean of 21 months after terminating treatment with IFNβ-1b. Post-treatment MRI activity was compared to baseline activity in these patients. Although contrast enhancing lesions (CEL) and the bulk white matter lesion load (BWMLL) on T2-weighted images eventually returned to baseline values, there was a refractory period of 6 - 10 months after terminating treatment, before baseline MRI activity was restored. Although the mechanism for a sustained effect of IFNβ-1b is unclear at this time, these results have important implications for enrollment of such patients into new treatment protocols that rely on contrast enhancing lesion frequency as an outcome measure.

AB - Monthly MRI activity and clinical disability were evaluated in two relapsing-remitting multiple sclerosis (RRMS) patients for 4 years during a crossover treatment trial with IFNβ-1b, and for a mean of 21 months after terminating treatment with IFNβ-1b. Post-treatment MRI activity was compared to baseline activity in these patients. Although contrast enhancing lesions (CEL) and the bulk white matter lesion load (BWMLL) on T2-weighted images eventually returned to baseline values, there was a refractory period of 6 - 10 months after terminating treatment, before baseline MRI activity was restored. Although the mechanism for a sustained effect of IFNβ-1b is unclear at this time, these results have important implications for enrollment of such patients into new treatment protocols that rely on contrast enhancing lesion frequency as an outcome measure.

KW - Interferon beta-1b

KW - Magnetic resonance imaging

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0033994836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033994836&partnerID=8YFLogxK

M3 - Article

C2 - 10773853

AN - SCOPUS:0033994836

SN - 1352-4585

VL - 6

SP - 86

EP - 90

JO - Multiple Sclerosis

JF - Multiple Sclerosis

IS - 2

ER -

MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this